Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521
about
Treatment of hypertension in black patients with angiotensin-converting enzyme inhibitorsChanges in indocyanine green kinetics after the administration of enalapril to healthy subjects.Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension.The influence of cilazapril on indices of autonomic function in normotensives and hypertensivesThe effect of captopril on the reflex control heart rate: possible mechanisms.A dose-response study of HOE 498, a new non-sulphydryl converting enzyme inhibitor, on blood pressure, pulse rate and the renin-angiotensin-aldosterone system in normal manAge and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilatThe pharmacodynamics and dose-response relationships of the angiotensin converting enzyme inhibitor, cilazapril, in essential hypertension.Heart rate control in hypertensive patients treated by captopril.Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients.Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertensionEffective dose range of enalapril in mild to moderate essential hypertension.The importance of renin-angiotensin blockade in patients with cardio-renal disease.Lisinopril: a new angiotensin-converting enzyme inhibitor.Enalapril: a long-acting angiotensin-converting enzyme inhibitor.Preclinical studies on angiotensin converting enzyme inhibitors.Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses.An overview of the clinical pharmacology of enalapril.Inhibitors of the angiotensin I converting enzyme as antihypertensive drugs.Converting-enzyme inhibitors increase converting-enzyme mRNA and activity in endothelial cells.The effect of enalapril on baroreceptor mediated reflex function in normotensive subjects.The effect of acute and chronic captopril therapy on baroreflex function in manLisinopril-induced vasculitis.Differences in the acute and chronic antihypertensive effects of lisinopril and enalapril assessed by ambulatory blood pressure monitoring.Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man.Effect of captopril on changes in plasma noradrenaline induced by sodium nitroprusside.Pharmacodynamic, pharmacokinetic and humoral effects of oral zabicipril, an angiotensin converting enzyme inhibitor in normotensive man.Haemodynamic and humoral effects of oral perindopril, an angiotensin converting enzyme inhibitor, in man.The effect of angiotensin II on endogenous noradrenaline release in man.Concentration effect modelling with converting enzyme inhibitors in man.Comparison between enalapril and lisinopril in mild-moderate hypertension: a comprehensive model for evaluation of drug efficacy.Lisinopril versus atenolol: decrease in systolic versus diastolic blood pressure with converting enzyme inhibition.Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure.Relationship of serum ACE inhibition to oral dose of enalapril in normotensive volunteers.Role of the renin-angiotensin system in systemic and regional vascular responses to orthostatic stress in healthy volunteers.Short- and long-term effects of spirapril on renal hemodynamics in patients with essential hypertension.Changes in haemodynamics and body fluid volume due to enalapril in patients with essential hypertension on chronic diuretic therapy.
P2860
Q24649589-08D5139E-BE08-446A-9DB5-D390EADABF48Q34357597-45DE4A0C-BA8A-47C0-9C1C-E822F9666F40Q34396973-51FF77BF-55A0-4800-BA7D-2E7755E5230AQ34397152-DD36FEB9-80B7-4BC7-9677-AF11C8A86E40Q34446559-45B23D21-0B9C-4DC8-826D-F2DF1696D5D8Q34446574-F988E857-A857-46A3-B622-11E896000114Q34447368-DEF8C1C1-4DA8-456B-AEA8-1B9AEF881C64Q34447895-71DE0549-DBD3-4871-A2D6-32BEDB1DA948Q34511533-2C65CA1E-E147-4636-A16D-13419017CC91Q34621057-1E99AE75-6D86-4BD1-9D47-3520985413AAQ34621390-C2DEC2EF-2AA9-4CF1-8AD6-B3BB13DCE90DQ34622710-7AF0A1DA-F67F-43A4-B100-C16219EB0A55Q37768511-3CBD4F3F-477B-4491-BADA-D32F67BB3223Q38282641-802BA162-4EB6-4BB7-A451-22211AB3DEE9Q39177686-DC6C0732-6D23-4156-A645-E5C78AC51516Q39612684-9CADDF98-416A-477B-8C50-3C38DD9B989CQ39680591-1D0A3AC5-03CD-4D73-9793-177C06CB7C7CQ40080622-2C37DB05-ACCA-4E66-845C-31C12DC37425Q40138907-420C8C70-5377-4339-A548-218DE1D44385Q41086220-EF7E439E-D4EA-4AEE-AE40-EEF6BDACC888Q41778599-F4ECDE32-8AA1-4F97-95E3-C904D967E96DQ42151850-591FDEC6-47EA-41A2-AFFD-779A98CC213BQ42200869-263651A6-F9B4-47EA-8F8E-079B020F7F01Q42288821-8483FF4E-F288-4F27-A01D-880F36B2EB8FQ42532122-9CC1AF90-A15B-47F3-A446-3FE1435F93B4Q42703150-F3725403-5718-4D93-8948-4CFD981B13D8Q43204747-C506C9FC-6659-4FD6-A2F3-171CAE7DA95DQ43228821-B2AAE31E-E520-4607-81F4-4CA6CE6F3995Q43229122-AF762E09-339C-41FC-AF1E-FFDF6C2FB9EDQ43261774-F191DF48-3071-4517-8BD6-8FF7FFEDF62AQ43475655-5AAA3BC5-B205-4061-8EB3-F7FBAC75CA97Q43807443-C5273BFA-4571-4950-8136-E846534ADCCBQ43924677-F383EDC4-5D4F-4685-AC7C-638B558C58EFQ43970879-65CF24E6-60A2-4B6D-880A-1A101211165AQ54184088-9C00D878-4C2A-4C95-88A0-3B10E2B92EA2Q54243543-24CBC97B-83B9-406D-8519-7230C36ACB40Q54438101-22F46A46-BFC6-4150-9E5A-542941785C68
P2860
Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年論文
@yue
1982年論文
@zh-hant
1982年論文
@zh-hk
1982年論文
@zh-mo
1982年論文
@zh-tw
1982年论文
@wuu
1982年论文
@zh
1982年论文
@zh-cn
name
Pharmacodynamics of converting ...... of MK421 (enalapril) and MK521
@en
type
label
Pharmacodynamics of converting ...... of MK421 (enalapril) and MK521
@en
prefLabel
Pharmacodynamics of converting ...... of MK421 (enalapril) and MK521
@en
P2093
P2860
P1476
Pharmacodynamics of converting ...... of MK421 (enalapril) and MK521
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.1982.TB01990.X
P407
P577
1982-09-01T00:00:00Z